Iniciar sesión Regístrese gratis

NeuroVive Pharmaceutical AB Quick ratio

¿Qué es el Quick ratio de NeuroVive Pharmaceutical AB?

El Quick ratio de NeuroVive Pharmaceutical AB es 7.99

¿Cuál es la definición de Quick ratio?



El ratio rápido es la relación de liquidez que mide la capacidad de una empresa para usar sus activos rápidos para cumplir con sus obligaciones a corto plazo de forma inmediata.

The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.

Quick ratio de compañías en Sector Health Care en OTC en comparadas con NeuroVive Pharmaceutical AB

¿Qué hace NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Empresas con quick ratio similar a NeuroVive Pharmaceutical AB